Home › NCT04043897
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
RecruitingPhase 2
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Collagenous colitis (CC) or lymphocytic colitis (LC) diagnosed on colon biopsies reviewed by 2 separate pathologists * CC will be defined histologically to be the following: thickness of the collagenous subepithelial table \>10 micrometer using an ocular micrometer, inflammation in the lamina propria consisting of mainly lymphocytes and plasma cells, lack of crypt architectural distortion, and regenerative-appearing changes in the surface and/or crypt epithelium * LC will be defined histologically to be the following: intraepithelial lymphocytes \>20 per 100 epithelial cells in the subjective area of highest lymphocyte density, inflammation in the lamina propria consisting of mainly lymphocytes and plasma cells, and regenerative-appearing changes in the surface and/or crypt epithelium * Subjects in active flare, defined as \>3 watery/loose stools per day on \>4 / 7 days over \>4 weeks in the past 3 months. Exclusion Criteria: \-
About the study
This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.
What is being tested
- Rifaximin 550mg (drug)
Sponsor: Eugene F Yen, MD · Participants: 10 · Started: Jun 29, 2018
Contact the study team
- Daniel Amusin, BS · Phone: 847-570-3558
- Iris Chiou, BA · Phone: 847-570-2138
Official record on ClinicalTrials.gov — NCT04043897
Locations in the U.S.
| Illinois | NorthShore University HealthSystem, Evanston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.